Urovant Sciences, Inc.: Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902

Study showed clinically meaningful impact on common symptoms of overactive bladder (OAB) compared to placebo from baseline to week 12 Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma

Related Keywords

China ,Japan ,United States ,Michigan ,Beaumont Hospital ,Royal Oak ,American ,Sumitomo Dainippon Pharma ,Sumitovant Biopharma ,Kenneth Peters ,Maya Frutiger ,Alana Darden Powell ,Cornelia Haag Molkenteller ,Linkedin ,Twitter ,American Urological Association ,Aboutsumitovant Biopharma Ltd ,Dainippon Pharmaceutical Co Ltd ,Oakland University William Beaumont School Of Medicine ,Corporate Communications ,Sumitomo Dainippon Pharma Co Ltd ,Pelvic Health Center ,Urovant Sciences ,Head Of Corporate Communications ,Sumitomo Pharmaceuticals Co Ltd ,Sumitovant Biopharma Ltd ,Beaumont Women ,Oakland University William Beaumont School ,New Orleans ,Dainippon Pharma ,Product Information ,Darden Powell ,Urovant ,Ciences ,Nnounces ,Positive ,Topline ,Results ,Hase ,Trial ,Potential ,Novel ,Gene ,Therapy ,